{"paper_id":"9d86f666-53eb-45c7-8759-bb28c7b8ceb5","body_text":"Vol.:(0123456789)1 3\nArchives of Gynecology and Obstetrics (2021) 303:965–966 \nhttps://doi.org/10.1007/s00404-020-05926-3\nCORRECTION\nCorrection to: Evaluation of the efficacy of fractional  CO2 laser \nin the treatment of vulvar and vaginal menopausal symptoms\nT. Sindou‑Faurie1  · C. Louis‑Vahdat2 · E. Oueld Es Cheikh1 · G. Canlorbe1 · J. L. Mergui1 · C. Uzan1 · H. Azaïs1\nPublished online: 7 January 2021 \n© Springer-Verlag GmbH Germany, part of Springer Nature 2021\nThe original article can be found online at https ://doi.org/10.1007/\ns0040 4-020-05868 -w.\n * H. Azaïs \n henriazais@gmail.com\n1 Department of Gynecologic and Breast Surgery \nand Oncology, AP-HP, Hôpitaux Universitaires Pitié \nSalpêtrière-Charles Foix, 47-83 boulevard de l’hôpital, \n75013 Paris, France\n2 Medicine Cabinet, 126 boulevard Saint-Germain, \n75006 Paris, France\nCorrection to:  Archives of Gynecology and Obstetrics  \nhttps ://doi.org/10.1007/s0040 4-020-05868 -w\nIn the original article published, the table 1 is incorrectly \npublished in a different language. The correct Table  1 is \ngiven below.\n\n966 Archives of Gynecology and Obstetrics (2021) 303:965–966\n1 3\nPublisher’s Note Springer Nature remains neutral with regard to \njurisdictional claims in published maps and institutional affiliations.\nTable 1  Patients characteristic \nand previous therapy for \ngenitourinary syndrome of \nmenopause\nSD standard deviation, BMI body mass index, MHT menopausal hormone therapy\nTotal (n = 46) University Hospi-\ntal (n = 32)\nMedicine cabinet \n(n = 14)\nP\nAge (years): mean ± SD 57.3 ± 11.1 57.4 ± 13.5 57.3 ± 10.2 0.958\nWeight (kg): mean ± SD 62.4 ± 14.2 68.7 ± 14.4 52.3 ± 5.5 0.0004\nHeight (cm): mean ± SD 163.1 ± 8.1 164.7 ± 8.2 161.5 ± 8.1 0.343\nBMI (kg/m2): mean ± SD 23.2 ± 4.7 25 ± 4.7 20.2 ± 3.2 0.003\nMenopause: n (%) 40 (87.0%) 30 (93.8%) 12 (85.7%) 0.574\nMHT use: n (%) 14 (30.4%) 7 (21.9%) 7 (50%) 0.084\nLocal hormone therapy use: n (%) 20 (43.5%) 13 (40.6%) 7 (50%) 0.748\nHyaluronic acid use: n (%) 11 (23.9%) 5 (15.6%) 6 (42.9%) 0.065\nLubricant use: n (%) 23 (50%) 11 (34.4%) 12 (85.7%) 0.003\nBreast cancer: n (%) 13 (28.3%) 13 (40.6%) 0 (0%) 0.004\nPelvic cancer: n (%) 5 (10.9%) 4 (12.5%) 1 (7.1%) 1\nPelvic radiation therapy: n (%) 3 (6.5%) 2 (6.3%) 1 (7.1%) 1\nBreast radiation therapy: n (%) 11 (23.9%) 11 (34.4%) 0 (0%) 0.020\nChemotherapy: n (%) 11 (23.9%) 10 (31.3%) 1 (7.1%) 0.133\nHormone therapy: n (%) 10 (21.7%) 10 (31.3%) 0 (0%) 0.020\nPremature ovarian failure: n (%) 3 (6.5%) 3 (9.4%) 0 (0%) 0.543","source_license":"CC0","license_restricted":false}